Kim, Jae Kwang

Park, Sang Un

Eldorado - Repository of the TU Dortmund

EXCLI Journal 2017;16:35-39 – ISSN 1611-2156 Received: December 04, 2016, accepted: January 04, 2017, published: January 10, 2017   35 Letter to the editor: PHARMACOLOGICAL ASPECTS OF GALANTAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE  Jae Kwang Kim1 and Sang Un Park2  1  Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, 406-772, Korea 2  Department of Crop Science, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Korea * Corresponding author: E-mail: supark@cnu.ac.kr, Tel.: +82-42-822-2631,  Fax: +82-42-822-2631   http://dx.doi.org/10.17179/excli2016-820   This is an Open Access article distributed under the terms of the Creative Commons Attribution License  (http://creativecommons.org/licenses/by/4.0/).    Dear Editor,  Galantamine is a natural product belonging to the isoquinoline alkaloid family of com-pounds. It was first discovered and isolated in the 1950s from Galanthus nivalis (common snowdrop) and Galanthus woronowii (Caucasian snowdrop), members of the Amaryllidaceae family (Marco and do Carmo Carreiras, 2006). Alzheimer’s disease (AD) is named after Dr. Alois Alzheimer, who first identified the dis-ease in 1906. AD slowly destroys memory and thinking skills and is the most frequently diag-nosed age-related neurodegenerative disorder (Prvulovic et al., 2010). Galantamine is an ace-tylcholinesterase (AChE) inhibitor and one of the most promising drugs available for the treat-ment of AD and various other memory impairments (Scott and Goa, 2000; Ago et al., 2011). Synthetic galantamine was first approved for the treatment of AD in Sweden in 2000 and was subsequently approved in the European Union and the United States (Heinrich and Lee Teoh, 2004). In the present report, we reviewed the most recent studies on the pharmacological activ-ity of galantamine (Table 1).   Table 1: Recent studies on the pharmacological activity of galantamine Key findings Reference No beneficial effects of galantamine therapy were observed in patients co-treated with memantine 2 years post treatment. The reasons for memantine treatment and the possibility of interactions between memantine and galantamine merit fur-ther investigation. Hager et al., 2016 Combination therapies using galantamine and cilostazol as well as the respective monotherapies maintained or even improved cognitive functions, affective func-tions, and activities of daily living functions in AD patients with asymptomatic la-cunar infarction. Hishikawa et al., 2016 Switching cholinesterase inhibitor (ChEI) drugs is clinically feasible for non-re-sponding patients with mild-to-moderate AD. Inclusion of galantamine in a switched group was as efficacious at maintaining cognition as that observed in a naïve group. Hwang et al., 2016  EXCLI Journal 2017;16:35-39 – ISSN 1611-2156 Received: December 04, 2016, accepted: January 04, 2017, published: January 10, 2017   36 Key findings Reference The use of rod-like hydroxyapatite particles for selective delivery of galantamine drug and nanoceria may become an extremely powerful method for drug delivery to affected brain areas of patients with AD. Wahba et al., 2016 Nasal galantamine hydrobromide/chitosan complex nanoparticles have been shown to be pharmacologically efficacious. Further, their safety has been demon-strated in vivo, confirming their potential to contribute to the intranasal manage-ment of AD. Hanafy et al., 2016 Galantamine enhances striatal dopamine release through allosteric modulation of α4 nicotinic acetylcholine receptors on nigrostriatal dopaminergic terminals. Inden et al., 2016Donepezil, tacrine, galantamine, and rivastigmine are known to cause convul-sions and have anticholinesterase effects. Further, they have been shown to de-crease locomotion in an invertebrate model. Bezerra et al., 2016 The bioavailability of galantamine hydrobromide-loaded solid-lipid nanoparticles is twice that of galantamine hydrobromide alone. Thus, these nanoparticle carri-ers show promise for safe and effective drug delivery, especially in diseases such as AD. Misra et al., 2016 Galantamine therapy, unlike donepezil, is characterized by a dual mechanism of action that may increase acetylcholine and the nicotinic receptor-modulation ef-fect within the frontal lobe, both of which are associated with apathy and execu-tive dysfunction in AD patients. Oka et al., 2016 Benefits to cognitive and affective functions were greater in AD patients receiving the combination therapy of galantamine plus ambulatory cognitive rehabilitation than in those receiving galantamine therapy only.  Tokuchi et al., 2016 Galantamine may be involved in modifying AD pathophysiological mechanisms by alleviating amyloid-β deposition and neuroinflammation. The results from this study provide new evidence for the use of galantamine in the treatment of AD. Wu et al., 2015 This is a long-term study examining the efficacy of galantamine in very elderly AD patients, suggesting improved efficacy in male patients and baseline lower cogni-tive, affective, and activity of daily living functions. Nakano et al., 2015 A galantamine derivative is emerging as a promising lead compound for multi-tar-get anti-AD therapy because of its strong inhibitory activity and ability to block amyloid beta deposition on acetylcholinesterase. Atanasova et al., 2015 Novel galantamine-loaded polymeric nanoparticles have been designed for the first time using a nano-emulsification approach. This study demonstrates the ap-propriate features required for advanced drug delivery systems to treat neuro-degenerative diseases. Fornaguera et al., 2015 The patch system (galantamine hydrobromide loaded gel drug reservoirs in transdermal patches) has moderate pH, high drug content, and a controlled drug-release pattern. Thus, the patch system has the potential to be used as a drug carrier system for the treatment of AD.  Woo et al., 2015 Memogain, a pro-drug, releases galantamine in the brain by cleavage with a car-boxyesterase. Nasal applications of memogain effectively deliver the drug to the brain of AD patients with the potential to retard plaque deposition and improve behavioral symptoms like those observed with galantamine treatment. Bhattacharya et al., 2015  Galantamine significantly improves cognitive, behavioral, and global performance in patients with AD. However, it needs to be used with caution in clinical settings. Jiang et al., 2015 Patients with mild cognitive impairment treated with galantamine had a lower rate of whole brain atrophy, but not hippocampal atrophy, over a 24-month treatment period than patients who were treated with placebo. However, the protective ef-fect of galantamine on the rate of whole brain atrophy in MCI was only observed in apolipoprotein E ϵ4 carriers. Prins et al., 2014 EXCLI Journal 2017;16:35-39 – ISSN 1611-2156 Received: December 04, 2016, accepted: January 04, 2017, published: January 10, 2017   37 Key findings Reference Soman is a nerve agent that reduces hippocampal glutamatergic synaptic trans-mission and may result in cognitive deficits long after an acute exposure. Preven-tion of soman-induced reductions in hippocampal glutamatergic synaptic trans-mission may be an important determinant of galantamine’s ability to counter the related cognitive deficits.  Alexandrova et al., 2014 Pre-treatment with galantamine in a newborn rat model of hypoxia-ischemia re-duced brain damage with a suppressive effect on microglial accumulation and in-terleukin-1 beta production. Furukawa et al., 2014 In addition to its previously known cognitive benefits, galantamine treatment im-proved quality of life in mixed dementia patients; however, the combination of galantamine and nimodipine was not advantageous. The small sample size of this study precludes any definitive conclusions. Caramelli et al., 2014 The combination of galantamine and memantine may be more effective at in-creasing selective cognition in schizophrenia patients than either medication alone. In the future, multitarget-directed ligands may play a role in the treatment of complex diseases like schizophrenia. Koola et al., 2014Galantamine promotes neurogenesis by activating the M1 muscarinic and α7 nic-otinic acetylcholine receptors. This study suggests that insulin-like growth factor 2 is also involved in the effects of galantamine on survival of 2-wk-old immature cells in the granule cell layer. Kita et al., 2014 Long-term treatment with galantamine significantly reduced mortality and declin-ing cognition and daily living activities in mild to moderate AD patients.Hager et al., 2014 In addition to improving cognitive and behavioral symptoms in AD, galantamine may have disease-modifying and neuroprotective properties, as indicated by de-layed amyloid β plaque formation and reduced gliosis.  Bhattacharya et al., 2014 Cognition, behavior, and activities of daily living improved during 12 months of galantamine treatment. At the 3-year follow-up, a decline in all outcomes was measured; however, cognition remained higher in the treated group than that in an untreated group. Richarz et al., 2014 This study examined the galantamine-associated reversal of scopolamine-in-duced learning and memory impairments.  Ramakrishnan et al., 2014   Acknowledgements This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Fu-ture Planning (2016M3A9A5919548).  Conflict of interest The authors declare no conflict of interest.  REFERENCES Ago Y, Koda K, Takuma K, Matsuda T. Pharmacolog-ical aspects of the acetylcholinesterase inhibitor galan-tamine. J Pharmacol Sci. 2011;116:6-17. Alexandrova EA, Alkondon M, Aracava Y, Pereira EF, Albuquerque EX. Galantamine prevents long-lasting suppression of excitatory synaptic transmission in CA1 pyramidal neurons of soman-challenged guinea pigs. Neurotoxicology. 2014;44:270-8.  Atanasova M, Stavrakov G, Philipova I, Zheleva D, Yordanov N, Doytchinova I. Galantamine derivatives with indole moiety: Docking, design, synthesis and ac-etylcholinesterase inhibitory activity. Bioorg Med Chem. 2015;23:5382-9. Bezerra da Silva C, Pott A, Elifio-Esposito S, Dalarmi L, Fialho do Nascimento K, Moura Burci L, et al. Ef-fect of Donepezil, Tacrine, Galantamine and Rivastig-mine on acetylcholinesterase inhibition in Dugesia ti-grina. Molecules. 2016;21:53. EXCLI Journal 2017;16:35-39 – ISSN 1611-2156 Received: December 04, 2016, accepted: January 04, 2017, published: January 10, 2017   38 Bhattacharya S, Haertel C, Maelicke A, Montag D. Galantamine slows down plaque formation and behav-ioral decline in the 5XFAD mouse model of Alzhei-mer's disease. PLoS One. 2014;9(2):e89454.  Bhattacharya S, Maelicke A, Montag D. Nasal applica-tion of the Galantamine Pro-drug Memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's Disease mice. J Alzheimers Dis. 2015;46:123-36. Caramelli P, Laks J, Palmini AL, Nitrini R, Chaves ML, Forlenza OV, et al. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Arq Neuropsiquiatr. 2014; 72:411-7. Fornaguera C, Feiner-Gracia N, Calderó G, García-Celma MJ, Solans C. Galantamine-loaded PLGA na-noparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegener-ative diseases. Nanoscale. 2015;7:12076-84. Furukawa S, Yang L, Sameshima H. Galantamine, an acetylcholinesterase inhibitor, reduces brain damage induced by hypoxia-ischemia in newborn rats. Int J Dev Neurosci. 2014;37:52-7. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, ran-domized, placebo-controlled study in Alzheimer's dis-ease. Neuropsychiatr Dis Treat. 2014;10:391-401. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimers Res Ther. 2016;8:47. Hanafy AS, Farid RM, Helmy MW, El Gamal SS. Pharmacological, toxicological and neuronal localiza-tion assessment of galantamine/chitosan complex na-noparticles in rats: future potential contribution in Alz-heimer's disease management. Drug Deliv. 2016; 23:3111-22. Heinrich M, Lee Teoh H. Galanthamine from snow-drop-the development of a modern drug against Alz-heimer's disease from local Caucasian knowledge. J Ethnopharmacol. 2004;92:147-62. Hishikawa N, Fukui Y, Sato K, Ohta Y, Yamashita T, Abe K. Comprehensive effects of galantamine and ci-lostazol combination therapy on patients with Alzhei-mer's disease with asymptomatic lacunar infarction. Geriatr Gerontol Int. 2016 Aug 31.  doi:10.1111/ggi.12870. epub ahead of print. Hwang TY, Ahn IS, Kim S, Kim DK. Efficacy of Galantamine on cognition in mild-to-moderate Alzhei-mer's Dementia after failure to respond to Donepezil. Psychiatry Invest. 2016;13:341-8. Inden M, Takata K, Yanagisawa D, Ashihara E, Tooyama I, Shimohama S, et al. α4 nicotinic acetyl-choline receptor modulated by galantamine on nigro-striatal terminals regulates dopamine receptor-medi-ated rotational behavior. Neurochem Int. 2016; 94:74-81. Jiang D, Yang X, Li M, Wang Y, Wang Y. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. J Neural Transm. 2015;122:1157-66. Kita Y, Ago Y, Higashino K, Asada K, Takano E, Ta-kuma K, et al. Galantamine promotes adult hippocam-pal neurogenesis via M₁ muscarinic and α7 nicotinic receptors in mice. Int J Neuropsychopharmacol. 2014;17:1957-68. Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, et al. Potential role of the combination of galantamine and memantine to im-prove cognition in schizophrenia. Schizophr Res. 2014;157:84-9. Marco L, do Carmo Carreiras M. Galanthamine, a nat-ural product for the treatment of Alzheimer's disease. Recent Pat CNS Drug Discov. 2006;1:105-11. Misra S, Chopra K, Sinha VR, Medhi B. Galantamine-loaded solid-lipid nanoparticles for enhanced brain de-livery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv. 2016;23:1434-43. Nakano Y, Matsuzono K, Yamashita T, Ohta Y, Hishi-kawa N, Sato K, et al. Long-term efficacy of Galanta-mine in Alzheimer's Disease: the Okayama Galanta-mine Study (OGS). J Alzheimers Dis. 2015; 47:609-17. Oka M, Nakaaki S, Negi A, Miyata J, Nakagawa A, Hirono N, et al. Predicting the neural effect of switch-ing from donepezil to galantamine based on single-photon emission computed tomography findings in pa-tients with Alzheimer's disease. Psychogeriatrics. 2016;16:121-34. Prins ND, van der Flier WA, Knol DL, Fox NC, Brashear HR, Nye JS, et al. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimers Res Ther. 2014;6:47.  EXCLI Journal 2017;16:35-39 – ISSN 1611-2156 Received: December 04, 2016, accepted: January 04, 2017, published: January 10, 2017   39 Prvulovic D, Hampel H, Pantel J. Galantamine for Alz-heimer's disease. Expert Opin Drug Metab Toxicol. 2010;6:345-54. Ramakrishnan L, Amatya C, DeSaer CJ, Dalhoff Z, Eggerichs MR. Galantamine reverses scopolamine-in-duced behavioral alterations in Dugesia tigrina. Invert Neurosci. 2014;14:91-101. Richarz U, Gaudig M, Rettig K, Schauble B. Galanta-mine treatment in outpatients with mild Alzheimer's disease. Acta Neurol Scand. 2014;129:382-92. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000;60:1095-122. Tokuchi R, Hishikawa N, Matsuzono K, Takao Y, Wakutani Y, Sato K, et al. Cognitive and affective ben-efits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease. Geri-atr Gerontol Int. 2016;16:440-5. Wahba SM, Darwish AS, Kamal SM. Ceria-containing uncoated and coated hydroxyapatite-based galanta-mine nanocomposites for formidable treatment of Alz-heimer's disease in ovariectomized albino-rat model. Mater Sci Eng C Mater Biol Appl. 2016;65: 151-63. Woo FY, Basri M, Masoumi HR, Ahmad MB, Ismail M. Formulation optimization of galantamine hydrobro-mide loaded gel drug reservoirs in transdermal patch for Alzheimer's disease. Int J Nanomed. 2015; 10:3879-86. Wu Z, Zhao L, Chen X, Cheng X, Zhang Y. Galanta-mine attenuates amyloid-β deposition and astrocyte ac-tivation in APP/PS1 transgenic mice. Exp Gerontol. 2015;72:244-50.  

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease

https://eldorado.tu-dortmund.de/bitstream/2003/35956/1/Park_10012017_proof.pdf

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease

Abstract

Similar works

Full text

Available Versions

Eldorado - Repository of the TU Dortmund